# Biotech's Next Generation and the Steel Industry's Green Pivot
MIT Technology Review has released its annual 35 Innovators Under 35 list, highlighting young scientists and entrepreneurs reshaping biotechnology. The roster underscores a fundamental shift in how biotech operates. Rather than concentrating on blockbuster drugs alone, emerging leaders focus on foundational tools, synthetic biology platforms, and therapeutic approaches that address previously untreatable conditions.
These under-35 innovators work across multiple domains. Some build computational frameworks that predict protein structures faster than traditional methods. Others engineer microorganisms to produce insulin, antibiotics, and rare compounds at lower cost and environmental impact than chemical synthesis. A subset tackles inherited genetic disorders through base editing and prime editing technologies, moving beyond older CRISPR approaches. Their collective work expands biotech beyond pharmaceuticals into agriculture, materials science, and industrial manufacturing.
The list matters because it reveals where venture capital and institutional research funding concentrate. Biotech in 2024 increasingly prioritizes efficiency, sustainability, and accessibility over pure profit margins on scarce treatments. Young founders attract capital precisely because they target systemic problems rather than incremental improvements to existing drug classes.
Parallel to biotech progress, the steel industry faces pressure to decarbonize. Traditional steelmaking accounts for roughly eight percent of global carbon emissions. The sector currently pursues two paths: hydrogen-based reduction and electric arc furnaces powered by renewable energy. Both require infrastructure investment and process redesign.
Cheaper, cleaner steel emerging from newer production methods changes downstream industries. Construction, automotive, renewable energy, and aerospace depend on affordable steel supply. A shift toward lower-carbon production expands addressable markets for these sectors without requiring carbon pricing or regulatory penalties. Companies investing in green steel production now position themselves ahead of likely future emission regulations and customer sustainability mandates.
The convergence of biotech innovation and industrial decarbonization reflects broader technology trends. Young entrepreneurs increasingly solve problems at system level rather than product level. Biotech founders don't just create new drugs; they build platforms that enable thousands of treatments. Steel innovators don't marginally improve furnaces; they redesign entire production chains using renewable energy and novel chemistry.
Both sectors demonstrate that breakthrough technologies require talent, capital, and regulatory clarity working in concert. The young biotech leaders on MIT's list succeeded because universities, venture firms, and government agencies aligned to support early-stage research. Similarly, green steel adoption accelerates when governments offer tax credits, corporations commit to procurement targets, and technology costs reach parity with incumbent methods.
The immediate implication for technology watchers is clear. Watch the under-35 cohort. Their choices reveal where institutional resources flow next. Track which biotech platforms gain adoption speed. Monitor green steel production capacity and cost curves. These indicators predict which industries transform first and which lag.
Neither biotech nor steel decarbonization solves overnight. Both require years of scaling, process optimization, and capital deployment. But the direction is set. The next decade belongs to engineers and scientists who make better biology and cleaner materials cheaper at scale.